cor2ed
engage checkpoint medical linkedin twitter
bg

Episodes 2 and 3: ASBMR 2022 Rare Bone Disease Highlights

Episodes 2 and 3: ASBMR 2022 Rare Bone Disease Highlights

In the second and third episodes of this podcast series, discover conference insights from the clinician and patient advocate perspectives

In the second and third episodes of this podcast series, discover conference insights from the clinician and patient advocate perspectives

Prof. Eric Rush, Ms. Inês Alves, Ms. Tracy Hart

Prof. Eric Rush (Children’s Mercy Hospital) and patient advocates Inês Alves (European Rare Bone Forum and ANDO Portugal) and Tracy Hart (Osteogenesis Imperfecta Foundation) share rare bone disease highlights from the ASBMR 2022 Annual Meeting. Downloadable educational infographics summarize their podcast highlights.

Portrait of Dr. Eric Rush
Prof. Eric Rush

Clinical Geneticist

Children’s Mercy, Kansas City, MO

United States (US)

Portrait of Ines Alves
Ms. Inês Alves

Patient advocacy

European Rare Bone Forum, Lisbon

Portugal

Ms. Tracy Hart

Patient advocacy

Osteogenesis Imperfecta Foundation

United States (US)

preview next

ASBMR 2022 Rare Bone Disease Highlights: Clinician Perspective

time Podcast | open 16 min | Sep 2022

temporal
Subscribe to our podcast series on:

I agree that this educational programme:

ASBMR 2022 Rare Bone Disease Highlights: Patient Advocate Perspective

time Podcast | open 23 min | Sep 2022

temporal
Subscribe to our podcast series on:

I agree that this educational programme:

In these two episodes, the experts review the latest pre-clinical and clinical research findings in fibrodysplasia ossificans progressiva (FOP), hypochondroplasia (HCH), osteogenesis imperfecta (OI), and autosomal dominant osteopetrosis. The rare bone disease patient experience is elevated in discussion of the IMPACT survey in OI, as is the role of patient advocacy in keeping patient and caregiver communities informed about research.

 

ASBMR logo

This educational activity was developed in partnership between COR2ED and the American Society for Bone and Mineral Research, supported by an independent medical education grant from the Rare Bone Disease Consortium, represented by Alexion, AstraZeneca Rare Disease, by Ipsen and by Kyowa Kirin, who had no input into selection of topics or speakers.

Other programmes of interest

preview next